Please assess the completion status of the following clinical trial:

Trial Title: Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* Pregnant women~* Ability to provide informed consent.~* Meets eligibility criteria for HAART initiation~Exclusion Criteria:~* Unwillingness to provide informed consent~* Below the age of legal consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine three-drug antiretroviral prophyalxis (Type: EXPERIMENTAL): Cohort of 160 HIV-infected women, approached at \> 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
- Control arm (Type: NO_INTERVENTION): A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).